Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ClinicalTrials.gov is a publicly accessible, Internet-based registry of clinical trials managed by the US National Library of Medicine that has the potential to address selective trial publication. Our objectives were to examine completeness of registration within ClinicalTrials.gov and to determine the extent and correlates of selective publication. METHODS AND FINDINGS: We examined reporting of registration information among a cross-section of trials that had been registered at ClinicalTrials.gov after December 31, 1999 and updated as having been completed by June 8, 2007, excluding phase I trials. We then determined publication status among a random 10% subsample by searching MEDLINE using a systematic protocol, after excluding trials completed after December 31, 2005 to allow at least 2 y for publication following completion. Among the full sample of completed trials (n = 7,515), nearly 100% reported all data elements mandated by ClinicalTrials.gov, such as intervention and sponsorship. Optional data element reporting varied, with 53% reporting trial end date, 66% reporting primary outcome, and 87% reporting trial start date. Among the 10% subsample, less than half (311 of 677, 46%) of trials were published, among which 96 (31%) provided a citation within ClinicalTrials.gov of a publication describing trial results. Trials primarily sponsored by industry (40%, 144 of 357) were less likely to be published when compared with nonindustry/nongovernment sponsored trials (56%, 110 of 198; p<0.001), but there was no significant difference when compared with government sponsored trials (47%, 57 of 122; p = 0.22). Among trials that reported an end date, 75 of 123 (61%) completed prior to 2004, 50 of 96 (52%) completed during 2004, and 62 of 149 (42%) completed during 2005 were published (p = 0.006). CONCLUSIONS: Reporting of optional data elements varied and publication rates among completed trials registered within ClinicalTrials.gov were low. Without greater attention to reporting of all data elements, the potential for ClinicalTrials.gov to address selective publication of clinical trials will be limited. Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trial registries are an important source of information for tracking clinical trials from their inception through to their reporting, and have been used to measure publication bias and outcome reporting bias.”
From Systematic review protocol assessing the processes for linking clinical trial registries and their published results (2016) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 2×
“Similarly unpublished clinical trials of rosiglitazone [3] identified from a company-maintained website and of erythropoiesis-stimulating agents [4] and antidepressants [5] found among data submitted to the FDA revealed important efficacy and safety information to be missing from the medical literature.”
BackgroundSelf-citationSilverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“Many studies have attempted to evaluate the extent of selective publication in the biomedical literature and found similarly low rates of publication [5,12–24], although none have used, to our knowledge, as large and as broadly representative a registry as ClinicalTrials.”
BackgroundSelective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 3×
“Similarly unpublished clinical trials of rosiglitazone [3] identified from a company-maintained website and of erythropoiesis-stimulating agents [4] and antidepressants [5] found among data submitted to the FDA revealed important efficacy and safety information to be missing from the medical literature.”
BackgroundResultPharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“However, we also found significantly different publication rates among study types and primary sponsors, consistent with prior research [11].”
ResultChan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845 · cited 1×
“Given the documented presence of outcome reporting bias among trials studied in other settings [5,12,13], the potential impact of ClinicalTrials.”
ResultRisk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741 · cited 1×
“Other evidence concerning selective publication is anecdotal, such as the absence of 6 mo of trial data from a key publication describing the efficacy of celecoxib [25,26], the delay of publication for two early trials of rofecoxib until after the medication was withdrawn from the market [27–29], and the aforementione…”
BackgroundSystematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546 · cited 1×
“Many studies have attempted to evaluate the extent of selective publication in the biomedical literature and found similarly low rates of publication [5,12–24], although none have used, to our knowledge, as large and as broadly representative a registry as ClinicalTrials.”
BackgroundClinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Dickersin, K. (1992) · JAMA · doi:10.1001/jama.1992.03480030052036 · Cited by 854
Cited by
Items 201–300 of 400
Pérez‐Mañá, C., Llonch, C., & Farré, M. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.06.009 · Cited by 15
Chen, K. Y., Borglund, E. M., Postema, E. C., Dunn, A. G., & Bourgeois, F. T. (2022) · Clinical Trials · doi:10.1177/17407745221093567 · Cited by 14
Zeitoun, J., Baron, G., Vivot, A., Atal, I., Downing, N. S., Ross, J. S., & Ravaud, P. (2017) · International Journal of Cancer · doi:10.1002/ijc.31061 · Cited by 13
Self-citationConsent Rates Reported in Published Pediatric Randomized Controlled Trials
Lonhart, J. A., Edwards, A. R., Agarwal, S., Lucas, B., & Schroeder, A. R. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.06.058 · Cited by 13
A scoping review of activities intended to reduce publication bias in randomised trials
Hohlfeld, A., Kredo, T., & Clarke, M. J. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02728-5 · Cited by 13
Mitigating the epidemic of type I error: ecology and evolution can learn from other disciplines
Parker, T. H., & Nakagawa, S. (2014) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2014.00076 · Cited by 13
The Role and Importance of Clinical Trial Registries and Results Databases
Zarin, D. A., Williams, R. J., Tse, T., & Ide, N. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-849905-4.00009-5 · Cited by 14
Piuzzi, N. S., Ng, M. K., Chughtai, M., Khlopas, A., Ramkumar, P. N., Harwin, S. F., Mont, M. A., Bauer, T. W., & Muschler, G. F. (2019) · Orthopedics · doi:10.3928/01477447-20190118-04 · Cited by 11
How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT)
Dufka, F. L., Dworkin, R. H., & Rowbotham, M. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000866 · Cited by 11
A snapshot and scorecard for analgesic clinical trials for chronic pain: The RReACT database
Greene, K. A., Dworkin, R. H., & Rowbotham, M. C. (2012) · Pain · doi:10.1016/j.pain.2012.06.004 · Cited by 12
Knowles, R. L., Ha, K. P., Mueller, J., Rawle, F. C., & Parker, R. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-035283 · Cited by 13
Publikationsbias in Abhängigkeit von der Art der Finanzierung bei klinischen Studien
Schott, G., Pachl, H., & Ludwig, W.-D. (2010) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2010.03.029 · Cited by 11
A Review of Skull Base Tumor Clinical Trials: Past Trends and Future Opportunities
Murchison, C., & Devaiah, A. K. (2016) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0036-1586759 · Cited by 11
Clinical trial registration and publication in acupuncture studies: a systematic review
MATSUURA, Y., Welch, N. T., SAKAI, T., & Tsutani, K. (2020) · Integrative Medicine Research · doi:10.1016/j.imr.2020.01.008 · Cited by 12
The ClinicalTrials.gov Results Database
Magee, L. A., & Menzies, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1103910 · Cited by 11
Kuntz, R. E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-12-201306180-00011 · Cited by 11
“Concerns of specious multiplicity of secondary data analyses, groundless litigation (2), exposure of confidential information for industry (3), and the desire for proprietary access to data in academia (3, 4) hinder the potential to improve public health and augment patient safety by sharing and pooling data sets resi…”
BackgroundCahan, A., & Anand, V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0185886 · Cited by 10
Bashir, R., & Dunn, A. G. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-013048 · Cited by 10
Dunn, A. G., Bourgeois, F. T., Murthy, S., Mandl, K. D., Day, R. O., & Coiera, E. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.279 · Cited by 10
Williams, M. J., Mullane, K., & Curtis, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804725-5.00005-7 · Cited by 13
Goodwin, T. R., Skinner, M. A., & Harabagiu, S. M. (2018) · PubMed Central · Cited by 13
Ross, S., Magee, L. A., WALKER, M. C., & Wood, S. L. (2012) · Trials · doi:10.1186/1745-6215-13-243 · Cited by 12
Schroll, J. B., Abdel-Sattar, M., & Bero, L. A. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.06.019 · Cited by 10
“Articles are often biased [1,2], and some studies are partially published or not published at all [3].”
BackgroundAnalysis of 473 US Head and Neck Cancer Trials (1996‐2014): Trends, Gaps, and Opportunities
Devaiah, A. K., & Murchison, C. (2015) · Otolaryngology · doi:10.1177/0194599815617723 · Cited by 12
“The rates of outcome reporting in our study—about 50%—are in line with those uncovered in previous investigations into general rates of data reporting in clinical trials.(18,21) This means that 50% of clinical trials for head and neck cancer therapies have not reported their results.”
BackgroundResultFincham, L., Hohlfeld, A., Clarke, M. J., Kredo, T., & McCaul, M. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-023-02110-4 · Cited by 10
“In other areas of health, similar trends were seen, for example one study reported that less than half of trials registered on clinicaltrials.gov had been published, while another reported that only 28.6% of the registered trials were published within 24 months of trial completion [26, 27].”
ResultInfluentialImplementación de la iniciativa de registro de ensayos clínicos
Revéiz, L., & Cuervo, L. G. (2011) · Colombian Journal of Anesthesiology · doi:10.5554/rca.v39i1.162 · Cited by 9
Burn clinical trials: A systematic review of registration and publications
Sinha, S., Yoon, G., Shin, W., Biernaskie, J. A., Nickerson, D., & Gabriel, V. (2017) · Burns · doi:10.1016/j.burns.2017.11.001 · Cited by 10
Huo, B., Ai, M., Jia, Y., Liu, Y. Z., Wang, Y., Yin, N., & Song, L. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01443-2 · Cited by 10
“All drug clinical trials being conducted as registration trials including phase I–IV drug trials and bioequivalence studies must be registered on the platform before enrolment of the first patient, and the NMPA is responsible for the validity and integrity of the data,[15] this will be useful to increase transparency…”
BackgroundGarg, S., Rizvi, A., Wee, D., Sreenivasan, A. K., Suchman, K. I., Thomas, S. L., Inamdar, S., & Trindade, A. J. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001517 · Cited by 9
Galsworthy, M. J., Irwin, R., Charlesworth, K., Ernst, K., Hristovski, D., Wismar, M., & McKee, M. (2013) · European Journal of Public Health · doi:10.1093/eurpub/ckt075 · Cited by 10
The heart of the matter: Outcome reporting bias and registration status in cardio-thoracic surgery
Wiebe, J. E., Detten, G., Scheckel, C., Gearhart, D., Wheeler, D., Sanders, D., & Vassar, M. B. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.098 · Cited by 10
Paul, M., Harbarth, S., Huttner, A., Thwaites, G. E., Theuretzbacher, U., Bonten, M. J. M., & Leibovici, L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa930 · Cited by 9
dos Santos, D. H. M., & Atallah, Á. N. (2015) · PeerJ · doi:10.7717/peerj.1015 · Cited by 12
“Furthermore, the literature suggests that investigators 346 rarely answer questions about the publication of their trials (Stern & Simes, 1997; Decullier, 347 2005; Ross et al., 2009).”
BackgroundInfluentialSridharan, K., & Sivaramakrishnan, G. (2016) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2015.09.003 · Cited by 8
“Studies that had assessed the publication fraction of registered clinical trials in the registry reported a publishing rate of only 46e70% [15,16].”
BackgroundLiang, R., Long, J., Zheng, Q., Yuan, G., Chen, X., Xin, Z., Lai, F., & Liu, Y. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01627-0 · Cited by 11
Richards, H. S., Cousins, S., Scroggie, D. L., Elliott, D., Macefield, R. C., Hudson, E., Mutanga, I. R., Shah, M., Alford, N., Blencowe, N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079654 · Cited by 8
Goswami, N. D., Tsalik, E. L., Naggie, S., Miller, W. C., Horton, J. R., Pfeiffer, C. D., & Hicks, C. B. (2014) · Trials · doi:10.1186/1745-6215-15-31 · Cited by 8
The publication symmetry test: a simple editorial heuristic to combat publication bias
Earp, B. D., & Wilkinson, D. J. C. (2017) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.2017s2.002 · Cited by 10
“[22] Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM.”
BackgroundBinko, M. A., Reitz, K. M., Chaer, R. A., Haga, L. M., Go, C. C., Alie-Cusson, F. S., Tzeng, E., Eslami, M. H., & Sridharan, N. D. (2023) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2023.05.035 · Cited by 9
Characteristics and Results of Pediatric Medical Device Studies: 2017–2022
Quazi, S., Narang, C., Espinoza, J., & Bourgeois, F. T. (2023) · PEDIATRICS · doi:10.1542/peds.2022-059842 · Cited by 9
Shaw, D. L., & Ross, J. S. (2015) · The AMA Journal of Ethic · doi:10.1001/journalofethics.2015.17.12.pfor1-1512 · Cited by 10
Self-citationResultados negativos na pesquisa científica: aspectos éticos
Guimarães, R. A. B., Succi, G. D. M., Montalli, V. Â. M., Niederauer, A. J. S., & Succi, R. C. D. M. (2018) · Revista Bioética · doi:10.1590/1983-80422018262245 · Cited by 8
Tan, Y. J., Crowley, R. J., & Ioannidis, J. P. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-48425-5 · Cited by 8
Grégory, J., Créquit, P., Vilgrain, V., Ronot, M., & Boutron, I. (2020) · European Radiology · doi:10.1007/s00330-020-06900-y · Cited by 10
“Regardless, the rate of available results is consistent with publication estimates in the field of oncology [28, 29].”
ResultLai, F., Pei, L., Chen, X., & Li, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.702261 · Cited by 8
Clinical Decision Making in Cardiology
Krumholz, H. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00004-4 · Cited by 8
Self-citationGershengorn, H. B. (2020) · Critical Care · doi:10.1186/s13054-020-03382-8 · Cited by 8
Ensuring Integrity in Comparative Effectiveness Research: Accentuate the Negative
Editors, T. P. M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000152 · Cited by 8
“With heightened vigilance on the part of journal editors and policymakers, such registration, by laying out intended analyses in advance, can prevent studies from shape-shifting or simply vanishing without explanation between registration and publication, as seems to be happening with many clinical trials [4].”
BackgroundNo publication bias in industry funded clinical trials of degenerative diseases of the spine
Son, C., Tavakoli, S., & Bartanusz, V. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.05.055 · Cited by 8
“A number of risk factors for non-publication of clinical trial data have been identified including industry funding [18,19].”
DiTosto, J. D., Steinberg, J. R., Turner, B. E., Weeks, B. T., Young, A. M. P., Lu, C. F., Wolgemuth, T. E., Holder, K., Laasiri, N., Squires, N. A., et al. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100696 · Cited by 7
Research waste among randomized controlled trials in ovarian cancer: A cross-sectional study
Lin, L., Tang, Y.-H., Yang, L., Wang, Y., & Chen, R. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108437 · Cited by 11
Holt, A. W., Troy, A. M., & Smalheiser, N. R. (2025) · Trials · doi:10.1186/s13063-025-08741-w · Cited by 7
“Only about half of registered trials result in any publications [1–3], and only about half of publications explicitly list the registry number [4, 5].”
Kim, N. Y., Bangdiwala, S. I., Thaler, K. J., & Gartlehner, G. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-27 · Cited by 7
About half of the noninferiority trials tested superior treatments: a trial-register based study
Gladstone, B. P., & Vach, W. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.10.011 · Cited by 7
“Our research had its own limitations, in particular, clinical trials register not being a perfect representation of all conducted trials [17].”
BackgroundPublication outcome of abstracts presented at the AACC annual meeting
Greene, D. N., Wilson, A. R., Bailey, N. M., & Schmidt, R. L. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.019 · Cited by 7
Asiimwe, I. G., & Rumona, D. (2016) · Research Integrity and Peer Review · doi:10.1186/s41073-016-0017-4 · Cited by 9
“report, studies providing completion dates are generally more likely to be published than those not providing the same dates [7].”
BackgroundPublication rate and characteristics of cancer clinical trials in India
Thomas, V. M., John, V. M., Alexander, S. A., Roy, A. M., & Mathew, A. (2020) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2020.100248 · Cited by 7
Dufka, F. L., Munch, T., Dworkin, R. H., & Rowbotham, M. C. (2015) · Pain · doi:10.1016/j.pain.0000000000000009 · Cited by 7
“We found the proportion of trials without available results to be similar across a diverse range of pain disorders and treatment strategies, as has been shown to be true in psychiatric disorders and other medical conditions.(10,11,13,17,19,23,24,33,36,48,50,51) Results are rarely available within a year of trial compl…”
BackgroundStudies of pain management in osteoarthritis: bedside to policy
Losina, E., Dervan, E. E., Daigle, M. E., & Katz, J. N. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2013.04.013 · Cited by 7
Goodwin, A. J., IV (2012) · CHEST Journal · doi:10.1378/chest.12-0519 · Cited by 7
Publication and outcome reporting of homeopathy trials registered in ClinicalTrials.gov
Thomas, E. T., Clark, J. M., & Glasziou, P. (2016) · Focus on Alternative and Complementary Therapies · doi:10.1111/fct.12278 · Cited by 7
Tan, S., Chen, Y., Dai, L., Zhong, C., Chai, N., Luo, X., Xu, J., Fu, X., Peng, Y., Linghu, E., et al. (2020) · Surgical Endoscopy · doi:10.1007/s00464-020-07786-z · Cited by 8
Gehle, H.-A., & Herrmann, H. (2020) · Journal of European CME · doi:10.1080/21614083.2020.1811557 · Cited by 7
“physicians or academic institutions is no better [16,17].”
BackgroundResult Publication of Chinese Trials in World Health Organization Primary Registries
Xuemei, L., Youping, L., Senlin, Y., & Shangqi, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012676 · Cited by 7
“found that the publication rate for trials primarily sponsored by the National Institutes of Health (NIH) is also just 40% (30/74) [15].”
BackgroundMethodInfluentialTrial registration in pediatric surgery trials
Rokhsefat, S., Morra, D. E., Offringa, M., Askie, L. M., & Kelly, L. E. (2017) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2017.10.049 · Cited by 7
Are results from pharmaceutical-company-sponsored studies available to the public?
Dal‐Ré, R., Pedromingo, A., García-Losa, M., Lahuerta, J. J., & Ortega, R. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0898-y · Cited by 6
“Although Cox regression analysis is used when assessing publication rate because of the nature of the data sets considered, we believe, as have others before [26], that our approach for a complete data set over a defined time period is more informative.”
MethodResultLee, C. J. (2013) · Episteme · doi:10.1017/epi.2013.35 · Cited by 6
“Further considerations include positive outcomes’ higher citation counts (Ioannidis 2005a) and the strength they lend to grant applications (Ross et al. 2009: 6).”
BackgroundRadun, I., Nilsonne, G., Radun, J. E., Helgesson, G., & Kecklund, G. (2018) · Transportation Research Part F Traffic Psychology and Behaviour · doi:10.1016/j.trf.2018.10.008 · Cited by 6
“In pharmaceutical research, it has been found that studies funded by pharmaceutical companies are less likely to be published if the results do not support the efficacy of the drug, compared to trials not funded by companies (Ross et al., 2009).”
ResultAdvancing research by publishing research protocols and negative studies
Agha, R. (2016) · International Journal of Surgery Protocols · doi:10.1016/j.isjp.2016.06.001 · Cited by 6
Predicting drug outcome of population via clinical knowledge graphPreprint
Brbić, M., Yasunaga, M., Agarwal, P., & Leskovec, J. (2024) · medRxiv · doi:10.1101/2024.03.06.24303800 · Cited by 10
“Given that the number of training examples is limited to clinical trials that reported re-sults [35, 36], we further tested whether a larger dataset could boost PlaNet’s performance.”
Publication Rates and Reported Results in a Cohort of Gene- and Cell-Based Therapy Trials
Coppens, D., Gardarsdóttir, H., van den Bogert, C. A., Bruin, M. L. D., Leufkens, H. G. M., & Hoekman, J. (2020) · Regenerative Medicine · doi:10.2217/rme-2019-0066 · Cited by 5
Mayer, M. G. (2015) · F1000Research · doi:10.12688/f1000research.7037.1 · Cited by 5
Wandalkar, P. P., Gandhe, P., Pai, A., Limaye, M. V., Chauthankar, S., Gogtay, N. J., & Thatte, U. M. (2017) · Perspectives in Clinical Research · doi:10.4103/2229-3485.215978 · Cited by 10
“We thus missed out on assessing certain aspects such as whether the trials were registered before enrolling the first subject or retrospectively and whether publication bias was associated with sponsorship of trials, which other studies have evaluated.[15,21,22] In addition, the study is limited by the fact that only…”
Yildirim‐Toruner, C., Pooni, R., Goh, Y. I., Becker‐Haimes, E. M., Dearing, J. W., Fernández, M. E., Morgan, E. M., Parry, G. J., Burnham, J. M., Ardoin, S. P., et al. (2022) · Pediatric Rheumatology · doi:10.1186/s12969-022-00665-y · Cited by 5
Ophthalmic pharmaceutical clinical trials: design considerations
Varner, P. (2015) · Clinical Investigation · doi:10.4155/cli.15.5 · Cited by 7
Patrone, D. (2010) · Journal of Medical Ethics · doi:10.1136/jme.2010.035378 · Cited by 6
Paludan‐Müller, A. S., Sharma, T., Rasmussen, K., & Gøtzsche, P. C. (2020) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200051 · Cited by 5
Chalmers, I. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2012-100583 · Cited by 5
Mayer, M. G. (2015) · F1000Research · doi:10.12688/f1000research.6878.1 · Cited by 5
El registro de los ensayos clínicos: necesario y obligado
Gurumeta, A. A. (2016) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2016.03.002 · Cited by 4
Boespflug, A. M., Gan, H. K., Chen, É. X., Pond, G. R., & You, B. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1651 · Cited by 4
Characteristics of stereotactic radiotherapy clinical trials registered on ClinicalTrials.gov
Zhang, X., Yang, D., Wang, C., & Huang, L. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-1189 · Cited by 4
“While the results of government-funded trials might be published selectively (22).”
BackgroundSecondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials
Beck, E. J., Sherry, A. D., Florez, M. A., Kouzy, R., Jaoude, J. A., Lin, T. A., Miller, A. M., Passy, A. H., Kupferman, G. S., Patel, R. R., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0265 · Cited by 4
Maru, S., Kuwatsuru, R., Matthias, M. D., & Simpson, R. J. (2025) · Journal of Medical Internet Research · doi:10.2196/60148 · Cited by 6
“Numerous studies using the ClinicalTrials.gov database have provided further evidence since [13-19].”
InfluentialA proposal for reducing the effect of one of many causes of publication bias
Richards, S. M., & Burrett, J. A. (2013) · Trials · doi:10.1186/1745-6215-14-41 · Cited by 4
Bolshete, P. (2017) · Ancient Science of Life · doi:10.4103/asl.asl_44_17 · Cited by 4
Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry
Ochi, N., Kawahara, T., Nagasaki, Y., Nakagawa, N., Yamagishi, T., Umemura, S., Honda, Y., Nakanishi, H., Yamane, H., & Takigawa, N. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy131 · Cited by 4
Results availability from clinical research of female urinary incontinence
Shamliyan, T., Kane, R. L., Wyman, J. F., & Sainfort, F. (2011) · Neurourology and Urodynamics · doi:10.1002/nau.21220 · Cited by 4
Are Phase 3 Clinical Trials Really Becoming More Complex?
Glass, H. E., DiFrancesco, J. J., Glass, L. M., & Tran, P. T. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479015583725 · Cited by 4
Trends in endpoint selection in clinical trials of advanced breast cancer
Song, S. Y., Seo, H., Kim, G., Kim, A. R., & Kim, E. Y. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2221-5 · Cited by 4
Strech, D., Sievers, S., Märschenz, S., Riedel, N., Wieschowski, S., Meerpohl, J. J., Langhof, H., Müller-Ohlraun, S., & Dirnagl, U. (2018) · F1000Research · doi:10.12688/f1000research.17022.1 · Cited by 4
Clinical trial transparency in gastrointestinal endoscopy research
Garg, S., Rizvi, A., Wee, D., Rizvi, Y., Rizvi, F., Rizvi, A., Thomas, S. L., Inamdar, S., & Trindade, A. J. (2022) · Endoscopy · doi:10.1055/a-1855-7870 · Cited by 4
Publication bias continues despite clinical-trial registration
Dolgin, E. (2009) · Nature · doi:10.1038/news.2009.902 · Cited by 5
Reider, B. J. (2012) · The American Journal of Sports Medicine · doi:10.1177/0363546512459510 · Cited by 4
Fair reporting of study results
Huttner, A., & Kaiser, L. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.02.015 · Cited by 4
The evolution of trial registration
(2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3021 · Cited by 4
Perez-Alija, J., Gallego, P., Linares, I., Ambroa, E., & Pedro, A. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016040 · Cited by 3
Otitis Media Trial Publication After ClinicalTrials.gov Registration
Oca, M., Rajan, S. M., & Qian, Z. J. (2025) · Otolaryngology · doi:10.1002/ohn.1366 · Cited by 4
“13,14 Despite widespread recognition of the profound implications of publication bias in clinical research, 9 few studies in the otolaryngology literature have examined publication discrepancies in clinical research trials.”
The Role and Importance of Clinical Trial Registries and Results Databases
Tse, T., Zarin, D. A., Williams, R. J., & Ide, N. C. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382167-6.00015-1 · Cited by 4
Metadata
- Authors
- Ross, J. S., Mulvey, G. K., Hines, E. M., Nissen, S. E., & Krumholz, H. M.
- Affiliations
- Health Services Research & Development (US)
- Yale New Haven Hospital (US)
- Amherst College (US)
- Cleveland Clinic (US)
- Corresponding author
- Ross, Joseph S.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-09-08
- Volume
- 6
- Issue
- 9
- Pages
- e1000144
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2728480
- OpenAlex
- W1970223153
- Cited by
- 401
- References
- 31
- Citations by year
- 2026: 17 · 2025: 10 · 2024: 15 · 2023: 10 · 2022: 16 · 2021: 20 · 2020: 18 · 2019: 14 · 2018: 23 · 2017: 27 · 2016: 38 · 2015: 39 · 2014: 36 · 2013: 35 · 2012: 32
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Veterans Affairs (K08 AG032886)
- Hartford Foundation for Public Giving
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Health Services Research and Development
- Cleveland Clinic
- Massachusetts Medical Society
- Daiichi-Sankyo
- Novo Nordisk
- National Institute on Aging (K08AG032886)
- U.S. National Library of Medicine
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Keywords
- ClinicalTrials.gov, clinical trial registration, selective publication, publication bias, registration completeness, industry funding, publication rates, clinical trial registries, primary outcome reporting
- MeSH terms
- Clinical Trials as Topic, Cross-Sectional Studies, Drug Industry, Financing, Government, Humans, National Library of Medicine (U.S.), Periodicals as Topic, Publishing, Registries, United States, Bibliometrics, Databases, Factual, Treatment Outcome, Internet, Information Dissemination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
